Madam Chair, like most members, I have received hundreds of communications from people and one just this past week from Mr. Yuri Korfschinsk who repeated the argument of the member for Etobicoke North about MS patients being discriminated against in terms of getting this treatment simply because they have MS and are at risk.
It was interesting that in his letter he says that the decisions to deny this treatment have resulted primarily based on the advice of MS neurologists, which is very strange to me. Their position was that the relationship between MS and CCSVI must be fully researched and documented before CCSVI can be treated in people with MS.
I wonder if the member is aware of whether neurologists have the requisite expertise to make that assessment and whether in fact they should be the authors of health care policy regarding CCSVI.